Literature DB >> 24047396

Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases.

Daniel Ansari1, Carlos Urey, Chinmay Gundewar, Monika Posaric Bauden, Roland Andersson.   

Abstract

UNLABELLED: OBJECTIVE. Mucin 4 (MUC4) is a transmembrane glycoprotein that is expressed in pancreatic ductal adenocarcinoma (PDAC), but not in normal pancreatic tissue. MUC4 has a proposed role in pancreatic tumor progression and metastasis. The purpose of this pilot study was to investigate MUC4 expression during PDAC metastasis by comparing the expression in the primary tumor and paired lymph node metastases from the same patient. MATERIAL AND METHODS. Surgical specimens from 17 cases of primary PDAC and paired lymph node metastases were immunohistochemically analyzed for MUC4 expression. The modified histochemical score (H-score) was used for staining assessment. RESULTS. Positive staining for MUC4 was detected in most primary and metastatic PDAC tumors (15/17 vs. 14/17). The concordance for MUC4 expression in primary tumors and corresponding lymph node metastases was 82%. In two cases, the primary tumor was MUC4-positive and the lymph node metastases were negative, while in one patient with a MUC4-negative primary tumor, the lymph node metastasis was positive. The distribution of H-score for expression of MUC4 significantly correlated (r = 0.615; p = 0.009) between primary tumors and paired metastatic lesions.
CONCLUSIONS: MUC4 was observed in both primary and matched metastatic tumors with a high level of concordance, suggesting that MUC4 expression is retained following PDAC metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047396     DOI: 10.3109/00365521.2013.832368

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?

Authors:  Marie Sahlin; Monika Posaric Bauden; Roland Andersson; Daniel Ansari
Journal:  Tumour Biol       Date:  2015-04-30

Review 2.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.

Authors:  Shailendra K Gautam; Sushil Kumar; Andrew Cannon; Bradley Hall; Rakesh Bhatia; Mohd Wasim Nasser; Sidharth Mahapatra; Surinder K Batra; Maneesh Jain
Journal:  Expert Opin Ther Targets       Date:  2017-05-29       Impact factor: 6.902

3.  Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions.

Authors:  Zachary E Stiles; Sheema Khan; Kurt T Patton; Meena Jaggi; Stephen W Behrman; Subhash C Chauhan
Journal:  HPB (Oxford)       Date:  2018-08-14       Impact factor: 3.647

Review 4.  Intervention on toll-like receptors in pancreatic cancer.

Authors:  Juan Vaz; Roland Andersson
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

5.  The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.

Authors:  Priya Pai; Satyanarayana Rachagani; Imayavaramban Lakshmanan; Muzafar A Macha; Yuri Sheinin; Lynette M Smith; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Mol Oncol       Date:  2015-10-19       Impact factor: 6.603

6.  Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Moorthy P Ponnusamy; Satyanarayana Rachagani; Imayavaramban Lakshmanan; Dhanya Haridas; Ying Yan; Apar K Ganti; Surinder K Batra
Journal:  Oncotarget       Date:  2015-03-10

7.  Genomic variants in mouse model induced by azoxymethane and dextran sodium sulfate improperly mimic human colorectal cancer.

Authors:  Qingfei Pan; Xiaomin Lou; Ju Zhang; Yinghui Zhu; Fuqiang Li; Qiang Shan; Xianwei Chen; Yingying Xie; Siyuan Su; Hanfu Wei; Liang Lin; Lin Wu; Siqi Liu
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

8.  Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.

Authors:  Gustavo A Arias-Pinilla; Angus G Dalgleish; Satvinder Mudan; Izhar Bagwan; Anthony J Walker; Helmout Modjtahedi
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.